Following the announcement of David Chang’s exit, Allogene’s executive changes are continuing with the company repositioning leadership around its CMO and R&D functions. The update places Zachary Roberts in the top role, starting June 30, consolidating late-stage accountability as the company manages CAR-T trial progression and platform execution. The shift also reflects broader operating transitions seen across cell therapy companies, where management changes are used to sharpen clinical focus and execution discipline amid tight timelines for pivotal trial reads and regulatory milestones. For stakeholders, the key near-term indicator is whether Allogene maintains momentum on program strategy and trial operational cadence under the new leadership structure.